摘要
目的探究分析晚期胃癌患者采用贝伐珠单抗联合化疗治疗的临床效果.方法选取2021年8月—2023年8月该院收治的70例晚期胃癌患者为研究对象,通过随机数字表法将其分为研究组与对照组,各35例.对照组采用化疗治疗,研究组采用贝伐珠单抗联合化疗治疗,比较两组的客观缓解率、疾病控制率、无进展生存时间、总生存时间、血清肿瘤标记物水平、生存质量评分、不良反应发生率.结果研究组客观缓解率为74.29%,疾病控制率为91.43%,均高于对照组的51.43%、68.57%,组间差异有统计学意义(P<0.05);研究组无进展生存时间为(6.85±0.79)个月,总生存时间为(9.64±1.43)个月,均长于对照组的(5.08±0.43)个月、(7.15±0.72)个月,组间差异有统计学意义(P<0.05);治疗后,研究组血清肿瘤标记物水平低于对照组,差异有统计学意义(P<0.05);治疗后,研究组生存质量评分高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论晚期胃癌患者采用贝伐珠单抗联合化疗治疗的效果显著,可降低血清肿瘤标记物水平,延长生存时间,提高生存质量,且贝伐珠单抗联合治疗方案未增加不良反应发生率,适合在医疗机构中推广应用.
Objective To explore the clinical effect of bevacizumab combined with chemotherapy in patients with advanced gastric cancer.Methods 70 patients with advanced gastric cancer admitted to our hospital from August 2021 to August 2023 were selected as the study objects,and were divided into a study group and a control group by random number table method,with 35 cases in each group.The control group was treated with chemotherapy,and the study group was treated with bevacizumab combined with chemotherapy.Objective response rate,disease control rate,progression-free survival time,overall survival time,serum tumor marker level,quality of life score and incidence of adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate of the study group were 74.29%and 91.43%,both higher than 51.43%and 68.57%in the control group,with statistical significance(P<0.05).The progression-free survival time of the study group was(6.85±0.79)months,and the total survival time was(9.64±1.43)months,both of which were longer than(5.08±0.43)months and(7.15±0.72)months of the control group,with statistical significance(P<0.05).After treatment,the level of serum tumor markers in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the Kanofsky Performance score of the study group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Bevacizumab combined with chemotherapy has a significant effect in the treatment of advanced gastric cancer patients,which can reduce the level of serum tumor markers,prolong the survival time and improve the quality of life.Moreover,bevacizumab combined treatment does not increase the incidence of adverse reactions,so it is suitable for promotion and application in medical institutions.
作者
李晓静
LI Xiaojing(Department of Oncology,The Fourth People's Hospital of Zibo(Zibo Cancer Hospital,(Zibo Infectious Disease Hospital),Zibo Luzhong Hospital of Traditional Chinese Medicine),Zibo Shandong,255000,China)
出处
《反射疗法与康复医学》
2024年第6期77-80,共4页
Reflexology And Rehabilitation Medicine
关键词
晚期胃癌
贝伐珠单抗
化疗
Advanced gastric cancer
Bevacizumab
Chemotherapy
作者简介
李晓静(1981-),女,山东济南人,本科,主治医师,研究方向:中西医结合治疗肿瘤。
